Amostomig Biosimilar - Anti-Leukocyte surface antigen CD47;PDL1 mAb - Research Grade
Source
Bispecific, CAS: 2889449-09-4
Origin species
Human
Expression system
XtenCHO
Purity
>95% by SDS-PAGE
Buffer
0.01M PBS, pH 7.4
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
anti-Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6, B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274
Reference
PX-TA2168-100
Note
For research use only. Not suitable for human use.
Isotype
IgG1-lambda
Clonality
Monoclonal Antibody
Description of Amostomig Biosimilar - Anti-Leukocyte surface antigen CD47;PDL1 mAb - Research Grade
“
The Structure of Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade
Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade is a therapeutic antibody that has been developed to target the surface antigens CD47 and PDL1. This biosimilar is a monoclonal antibody, meaning it is made up of identical immune cells that have been cloned from a single parent cell. It is designed to mimic the structure and function of the original therapeutic antibody, while also providing a more cost-effective option for patients.
The antibody is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains contain a constant region and a variable region, while the light chains only have a variable region. The variable regions are responsible for binding to the specific targets, CD47 and PDL1, on the surface of leukocytes. This binding is crucial for the therapeutic activity of the antibody.
The Activity of Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade
The main activity of Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade is to block the interaction between CD47 and PDL1. CD47 is a protein that is found on the surface of many types of cells, including leukocytes. It acts as a “”don’t eat me”” signal, preventing the immune system from attacking these cells. PDL1, on the other hand, is a protein found on the surface of cancer cells and other cells in the body. It interacts with PD1 receptors on immune cells, inhibiting their activity and allowing cancer cells to evade detection and destruction by the immune system.
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade” Cancel reply
Related products
Isotype Control
Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Reviews
There are no reviews yet.